Who is sponsoring NCT00006206?

NCT00006206 is sponsored by University of North Carolina, Chapel Hill.

What condition does NCT00006206 study?

NCT00006206 studies Alcoholism.

What drugs are being tested in NCT00006206?

Interventions: naltrexone (Revia), acamprosate (Campral).

What is the status of NCT00006206?

NCT00006206 is currently COMPLETED.

Last reviewed 2010-04-30 · How we verify

COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions

NCT00006206 Phase 3 COMPLETED

Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking.

Details

Lead sponsor	University of North Carolina, Chapel Hill
Phase	Phase 3
Status	COMPLETED
Enrolment	1375
Start date	1997-08
Completion	2006-05

Conditions

Alcoholism

Interventions

naltrexone (Revia)
acamprosate (Campral)

Primary outcomes

Percent days abstinent
Time to relapse to heavy drinking

Countries

United States